Business
Thermo Fisher Scientific Receives 510(k) Clearance in the United States for EXENT System* to Aid in the Diagnosis of Multiple Myeloma
WALTHAM, Mass., November 12, 2025--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced 510(k) clearance of the EXENT® Analyser and Immunoglobulin Isotypes (GAM) Assay**, a first-of-its-kind automated platform for clinical laboratories. The EXENT System combines enhanced sensitivity and automation to provide accurate results, helping clinicians make a fast diagnosis for patients with multiple myeloma and related disorders.
About this update from Thermo Fisher Scientific Inc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1590,"height":341,"url":"https://media.zenfs.com/en/business-wire.com/d3aa83da2f0f21f69dc252f23a92c413"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/97exynRejxNCmcfx1jrIOw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIwNjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/d3aa83da2f0f21f69dc252f23a92c413","width":960,"height":206},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/yUhMcpJzO6EOImrpVNrchg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01MTQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/d3aa83da2f0f21f69dc252f23a92c413","width":1200,"height":257}},"lazy":false},{"type":"text","content":"First-of-its-kind, automated system delivers increased sensitivity, specific identification of disease markers and improved laboratory workflow to support fast, confident diagnoses","length":180,"tagName":"p","attribs":{}},{"type":"text","content":"WALTHAM, Mass., November 12, 2025--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced 510(k) clearance of the EXENT® Analyser and Immunoglobulin Isotypes (GAM) Assay**, a first-of-its-kind automated platform for clinical laboratories. The EXENT System combines enhanced sensitivity and automation to provide accurate results, helping clinicians make a fast diagnosis for patients with multiple myeloma and related disorders.","length":486,"tagName":"p"},{"type":"text","content":"According to the International Myeloma Foundation, more than 176,000 people are diagnosed with multiple myeloma worldwide each year, yet the current diagnostic pathway can be slow and uncertain, often relying on highly subjective interpretation of test results. The EXENT System is designed to address this challenge by detecting and isotyping M-proteins, abnormal antibodies produced by cancerous plasma cells, at low concentrations. By providing clear, automated results that reduce the need for interpretation, the system gives clinicians a reliable view of a patient’s condition and supports early, confident diagnoses.","length":623,"tagName":"p"},{"type":"text","content":""The clearance of the EXENT System represents a significant advancement in the tools available to aid in the diagnosis of multiple myeloma," said ...